In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

Nat Med. 1995 Dec;1(12):1284-90. Unique Identifier : AIDSLINE MED/96083629
Chun TW; Finzi D; Margolick J; Chadwick K; Schwartz D; Siliciano RF; Department of Medicine, Johns Hopkins University School of; Medicine, Baltimore, Maryland 21205, USA.

Abstract: Although it is presumed that the integration of HIV-1 into the genome of infected CD4+ T lymphocytes allows viral persistence, there has been little direct evidence that CD4+ T cells with integrated provirus function as a latent reservoir for HIV-1 in infected individuals. Using resting CD4+ T-cell populations of extremely high purity and a novel assay that selectively and unambiguously detects integrated HIV-1, we show that resting CD4+ T cells harbouring integrated provirus are present in some infected individuals. However, these cells do not accumulate within the circulating pool of resting CD4+ T cells in the early stages of HIV-1 infection and do not accumulate even after prolonged periods in long-term survivors of HIV-1 infection. These results suggest that because of viral cytopathic effects and/or host effector mechanisms, productively infected CD4+ T cells do not generally survive for long enough to revert to a resting memory state in vivo.

Keywords: Base Sequence Cell Separation CD4-Positive T-Lymphocytes/*VIROLOGY DNA Primers DNA, Viral/*ANALYSIS Human HIV Infections/BLOOD/*VIROLOGY HIV-1/*GENETICS/ISOLATION & PURIF Molecular Sequence Data Polymerase Chain Reaction Proviruses/*GENETICS Support, U.S. Gov't, P.H.S. Virus Integration Virus Latency JOURNAL ARTICLE
960330
M9630728

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .